Kramer was the CEO of Emergent BioSolutions, a government contractor hired to mass produce coronavirus vaccine doses, 400 ...
Robert G. Kramer sold nearly 90,000 shares of his stock in Emergent BioSolutions, knowing that large quantities of vaccine ...
Daily Voice on MSN
NY AG sues former Emergent CEO over insider trading
A former biotech CEO pocketed more than $10 million by selling company stock after learning of serious COVID-19 vaccine ...
A surge in deals and financings had the industry abuzz heading into this year’s J.P. Morgan Healthcare Conference. But some ...
Zhengye receives a Nasdaq notice for failing to file its 2024 annual report on time. The company has 60 days to submit a compliance plan to avoid potential delisting. Get special access to three ...
TRINITY BIOTECH ($TRIB) is expected to release its quarterly earnings data on Thursday, May 22nd before market open, per Finnhub. Analysts are expecting revenue of ...
I favor biotech stocks trading below cash value after setbacks; Arvinas (ARVN) fits this description, dropping 25% on Thursday after ending two Phase 3 trials. ARVN's net cash per share is over $12, ...
09:35 EDT Zhengye Biotechnology (ZYBT) Holding Ltd trading halted, volatility trading pause Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor ...
Fortress Biotech amended a credit agreement to extend its maturity. The stock rose 4.8% to $4.40 in after-hours trading Monday. Par Technology was selected to be Papa John's International's new ...
Oncolytics Biotech (NASDAQ:ONCY – Get Free Report)‘s stock had its “hold” rating reissued by research analysts at Jones Trading in a report released on Friday,Benzinga reports. Several other equities ...
(RTTNews) - Several small- and mid-cap stocks posted notable gains in Wednesday's after-hours trading session, even though most companies did not release fresh news. The movement was largely driven by ...
24/7 Wall St. on MSN
Biotech Could Be One of 2026’s Biggest Winners, and This ETF Is Perfectly Positioned
Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results